De  Yang, M.D., Ph.D.

De Yang, M.D., Ph.D.

  • Center for Cancer Research
  • National Cancer Institute


My current research on alarmins focuses on three major areas: 1) identification of additional alarmins, 2) elucidation of the mechanism(s) by which various alarmins chemoattract and activate dendritic cells (DCs), and 2) testing the potential use of alarmins as adjuvants for experimental tumor immunotherapy.

Areas of Expertise



Selected Publications

Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer

Nie Y, He J, Shirota H, Trivett AL, Yang D, Klinman DM, Oppenheim JJ, Chen X
Sci. Signal. 11: 2018. [ Journal Article ]

Alarmins and immunity

Yang D, Han Z, Oppenheim JJ
Immunol. Rev. 280: 41-56, 2017. [ Journal Article ]

Development of a curative therapeutic vaccine (TheraVac) for the treatment of large established tumors

Nie Y, Yang D, Trivett A, Han Z, Xin H, Chen X, Oppenheim JJ
Sci. Rep. 7: 14186, 2017. [ Journal Article ]

Therapeutic vaccine to cure large mouse hepatocellular carcinomas

Han Z, Yang D, Trivett A, Oppenheim JJ
Oncotarget. 8: 52061-52071, 2017. [ Journal Article ]

A role for neuronal alpha-synuclein in gastrointestinal immunity

Stolzenberg E, Berry D, Yang D, Lee EY, Kroemer A, Kaufman S, Wong GCL, Oppenheim JJ, Sen S, Fishbein T, Bas A, Harris B, Barbut D Zasloff MA
J. Innate Immun. 9: 456-463, 2017. [ Journal Article ]